Skip to main content
Top
Published in: Journal of Translational Medicine 1/2024

Open Access 01-12-2024 | Molecular Imaging | Research

Removal of endothelial surface-associated von villebrand factor suppresses accelerate datherosclerosis after myocardial infarction

Authors: Koya Ozawa, William Packwood, Matthew A Muller, Yue Qi, Aris Xie, Oleg Varlamov, Owen J. McCarty, Dominic Chung, José A. López, Jonathan R. Lindner

Published in: Journal of Translational Medicine | Issue 1/2024

Login to get access

Abstract

Background

Thromboinflammation involving platelet adhesion to endothelial surface-associated von Willebrand factor (VWF) has been implicated in the accelerated progression of non-culprit plaques after MI. The aim of this study was to use arterial endothelial molecular imaging to mechanistically evaluate endothelial-associated VWF as a therapeutic target for reducing remote plaque activation after myocardial infarction (MI).

Methods

Hyperlipidemic mice deficient for the low-density lipoprotein receptor and Apobec-1 underwent closed-chest MI and were treated chronically with either: (i) recombinant ADAMTS13 which is responsible for proteolytic removal of VWF from the endothelial surface, (ii) N-acetylcysteine (NAC) which removes VWF by disulfide bond reduction, (iii) function-blocking anti-factor XI (FXI) antibody, or (iv) no therapy. Non-ischemic controls were also studied. At day 3 and 21, ultrasound molecular imaging was performed with probes targeted to endothelial-associated VWF A1-domain, platelet GPIbα, P-selectin and vascular cell adhesion molecule-1 (VCAM-1) at lesion-prone sites of the aorta. Histology was performed at day 21.

Results

Aortic signal for P-selectin, VCAM-1, VWF, and platelet-GPIbα were all increased several-fold (p < 0.01) in post-MI mice versus sham-treated animals at day 3 and 21. Treatment with NAC and ADAMTS13 significantly attenuated the post-MI increase for all four molecular targets by > 50% (p < 0.05 vs. non-treated at day 3 and 21). On aortic root histology, mice undergoing MI versus controls had 2–4 fold greater plaque size and macrophage content (p < 0.05), approximately 20-fold greater platelet adhesion (p < 0.05), and increased staining for markers of platelet transforming growth factor-β1 signaling. Accelerated plaque growth and inflammatory activation was almost entirely prevented by ADAMTS13 and NAC. Inhibition of FXI had no significant effect on molecular imaging signal or plaque morphology.

Conclusions

Plaque inflammatory activation in remote arteries after MI is strongly influenced by VWF-mediated platelet adhesion to the endothelium. These findings support investigation into new secondary preventive therapies for reducing non-culprit artery events after MI.
Appendix
Available only for authorised users
Literature
3.
go back to reference Ozawa K, Muller MA, Varlamov O, Tavori H, Packwood W, Mueller PA, Xie A, Ruggeri Z, Chung D, Lopez JA, Lindner JR. Proteolysis of Von Willebrand factor influences endothelial activation and vascular compliance in atherosclerosis. JACC Basic Transl Sci. 2020;5:1017–28.CrossRefPubMedPubMedCentral Ozawa K, Muller MA, Varlamov O, Tavori H, Packwood W, Mueller PA, Xie A, Ruggeri Z, Chung D, Lopez JA, Lindner JR. Proteolysis of Von Willebrand factor influences endothelial activation and vascular compliance in atherosclerosis. JACC Basic Transl Sci. 2020;5:1017–28.CrossRefPubMedPubMedCentral
5.
go back to reference Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35.CrossRefPubMed Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35.CrossRefPubMed
6.
go back to reference Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, Iwamoto Y, Thompson B, Carlson AL, Heidt T, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325–9.CrossRefPubMedPubMedCentral Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, Iwamoto Y, Thompson B, Carlson AL, Heidt T, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325–9.CrossRefPubMedPubMedCentral
7.
go back to reference Fang L, Moore XL, Dart AM, Wang LM. Systemic inflammatory response following acute myocardial infarction. J Geriatr Cardiol. 2015;12:305–12.PubMedPubMedCentral Fang L, Moore XL, Dart AM, Wang LM. Systemic inflammatory response following acute myocardial infarction. J Geriatr Cardiol. 2015;12:305–12.PubMedPubMedCentral
8.
go back to reference Ong SB, Hernandez-Resendiz S, Crespo-Avilan GE, Mukhametshina RT, Kwek XY, Cabrera-Fuentes HA, Hausenloy DJ. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018;186:73–87.CrossRefPubMedPubMedCentral Ong SB, Hernandez-Resendiz S, Crespo-Avilan GE, Mukhametshina RT, Kwek XY, Cabrera-Fuentes HA, Hausenloy DJ. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018;186:73–87.CrossRefPubMedPubMedCentral
9.
go back to reference Moccetti F, Brown E, Xie A, Packwood W, Qi Y, Ruggeri Z, Shentu W, Chen J, Lopez JA, Lindner JR. Myocardial infarction produces sustained proinflammatory endothelial activation in remote arteries. J Am Coll Cardiol. 2018;72:1015–26.CrossRefPubMedPubMedCentral Moccetti F, Brown E, Xie A, Packwood W, Qi Y, Ruggeri Z, Shentu W, Chen J, Lopez JA, Lindner JR. Myocardial infarction produces sustained proinflammatory endothelial activation in remote arteries. J Am Coll Cardiol. 2018;72:1015–26.CrossRefPubMedPubMedCentral
10.
go back to reference Kang J, Jeon KH, Kim SW, Park JJ, Yoon CH, Suh JW, Cho YS, Youn TJ, Chae IH, Choi DJ. Evolution of nonculprit coronary atherosclerotic plaques assessed by serial virtual histology intravascular ultrasound in patients with ST-segment elevation myocardial infarction and chronic total occlusion. Coron Artery Dis. 2016;27:650–7.CrossRefPubMedPubMedCentral Kang J, Jeon KH, Kim SW, Park JJ, Yoon CH, Suh JW, Cho YS, Youn TJ, Chae IH, Choi DJ. Evolution of nonculprit coronary atherosclerotic plaques assessed by serial virtual histology intravascular ultrasound in patients with ST-segment elevation myocardial infarction and chronic total occlusion. Coron Artery Dis. 2016;27:650–7.CrossRefPubMedPubMedCentral
11.
go back to reference Liu Y, Davidson BP, Yue Q, Belcik T, Xie A, Inaba Y, McCarty OJ, Tormoen GW, Zhao Y, Ruggeri ZM, et al. Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging. 2013;6:74–82.CrossRefPubMed Liu Y, Davidson BP, Yue Q, Belcik T, Xie A, Inaba Y, McCarty OJ, Tormoen GW, Zhao Y, Ruggeri ZM, et al. Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging. 2013;6:74–82.CrossRefPubMed
12.
go back to reference Shim CY, Liu YN, Atkinson T, Xie A, Foster T, Davidson BP, Treible M, Qi Y, Lopez JA, Munday A, et al. Molecular Imaging of Platelet-Endothelial Interactions and Endothelial Von Willebrand Factor in early and mid-stage atherosclerosis. Circ Cardiovasc Imaging. 2015;8:e002765.CrossRefPubMed Shim CY, Liu YN, Atkinson T, Xie A, Foster T, Davidson BP, Treible M, Qi Y, Lopez JA, Munday A, et al. Molecular Imaging of Platelet-Endothelial Interactions and Endothelial Von Willebrand Factor in early and mid-stage atherosclerosis. Circ Cardiovasc Imaging. 2015;8:e002765.CrossRefPubMed
13.
go back to reference Chen J, Fu X, Wang Y, Ling M, McMullen B, Kulman J, Chung DW, Lopez JA. Oxidative modification of Von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010;115:706–12.CrossRefPubMedPubMedCentral Chen J, Fu X, Wang Y, Ling M, McMullen B, Kulman J, Chung DW, Lopez JA. Oxidative modification of Von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010;115:706–12.CrossRefPubMedPubMedCentral
14.
go back to reference Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res. 2005;96:612–6.CrossRefPubMed Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res. 2005;96:612–6.CrossRefPubMed
17.
go back to reference Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, Ni H, Lopez JA. N-acetylcysteine reduces the size and activity of Von Willebrand factor in human plasma and mice. J Clin Invest. 2011;121:593–603.CrossRefPubMedPubMedCentral Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, Ni H, Lopez JA. N-acetylcysteine reduces the size and activity of Von Willebrand factor in human plasma and mice. J Clin Invest. 2011;121:593–603.CrossRefPubMedPubMedCentral
18.
go back to reference Garland KS, Reitsma SE, Shirai T, Zilberman-Rudenko J, Tucker EI, Gailani D, Gruber A, McCarty OJT, Puy C. Removal of the C-Terminal domains of ADAMTS13 by activated coagulation factor XI induces platelet adhesion on endothelial cells under Flow conditions. Front Med (Lausanne). 2017;4:232.CrossRefPubMed Garland KS, Reitsma SE, Shirai T, Zilberman-Rudenko J, Tucker EI, Gailani D, Gruber A, McCarty OJT, Puy C. Removal of the C-Terminal domains of ADAMTS13 by activated coagulation factor XI induces platelet adhesion on endothelial cells under Flow conditions. Front Med (Lausanne). 2017;4:232.CrossRefPubMed
19.
go back to reference Kaufmann BA, Carr CL, Belcik JT, Xie A, Yue Q, Chadderdon S, Caplan ES, Khangura J, Bullens S, Bunting S, Lindner JR. Molecular imaging of the initial inflammatory response in atherosclerosis: implications for early detection of disease. Arterioscler Thromb Vasc Biol. 2010;30:54–9.CrossRefPubMed Kaufmann BA, Carr CL, Belcik JT, Xie A, Yue Q, Chadderdon S, Caplan ES, Khangura J, Bullens S, Bunting S, Lindner JR. Molecular imaging of the initial inflammatory response in atherosclerosis: implications for early detection of disease. Arterioscler Thromb Vasc Biol. 2010;30:54–9.CrossRefPubMed
20.
go back to reference Powell-Braxton L, Veniant M, Latvala RD, Hirano KI, Won WB, Ross J, Dybdal N, Zlot CH, Young SG, Davidson NO. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med. 1998;4:934–8.CrossRefPubMed Powell-Braxton L, Veniant M, Latvala RD, Hirano KI, Won WB, Ross J, Dybdal N, Zlot CH, Young SG, Davidson NO. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med. 1998;4:934–8.CrossRefPubMed
21.
go back to reference Chen J, Ling M, Fu X, Lopez JA, Chung DW. Simultaneous exposure of sites in Von Willebrand factor for glycoprotein ib binding and ADAMTS13 cleavage: studies with ristocetin. Arterioscler Thromb Vasc Biol. 2012;32:2625–30.CrossRefPubMed Chen J, Ling M, Fu X, Lopez JA, Chung DW. Simultaneous exposure of sites in Von Willebrand factor for glycoprotein ib binding and ADAMTS13 cleavage: studies with ristocetin. Arterioscler Thromb Vasc Biol. 2012;32:2625–30.CrossRefPubMed
22.
go back to reference Ngo ATP, Jordan KR, Mueller PA, Hagen MW, Reitsma SE, Puy C, Revenko AS, Lorentz CU, Tucker EI, Cheng Q, et al. Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. J Thromb Haemost. 2021;19:1001–17.CrossRefPubMedPubMedCentral Ngo ATP, Jordan KR, Mueller PA, Hagen MW, Reitsma SE, Puy C, Revenko AS, Lorentz CU, Tucker EI, Cheng Q, et al. Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. J Thromb Haemost. 2021;19:1001–17.CrossRefPubMedPubMedCentral
23.
go back to reference Ozawa K, Packwood W, Varlamov O, Qi Y, Xie A, Wu MD, Ruggeri Z, Lopez JA, Lindner JR. Molecular Imaging of VWF (Von Willebrand factor) and platelet adhesion in Postischemic impaired Microvascular Reflow. Circ Cardiovasc Imaging. 2018;11:e007913.CrossRefPubMedPubMedCentral Ozawa K, Packwood W, Varlamov O, Qi Y, Xie A, Wu MD, Ruggeri Z, Lopez JA, Lindner JR. Molecular Imaging of VWF (Von Willebrand factor) and platelet adhesion in Postischemic impaired Microvascular Reflow. Circ Cardiovasc Imaging. 2018;11:e007913.CrossRefPubMedPubMedCentral
24.
go back to reference McCarty OJ, Conley RB, Shentu W, Tormoen GW, Zha D, Xie A, Qi Y, Zhao Y, Carr C, Belcik T, et al. Molecular imaging of activated Von Willebrand factor to detect high-risk atherosclerotic phenotype. JACC Cardiovasc Imaging. 2010;3:947–55.CrossRefPubMedPubMedCentral McCarty OJ, Conley RB, Shentu W, Tormoen GW, Zha D, Xie A, Qi Y, Zhao Y, Carr C, Belcik T, et al. Molecular imaging of activated Von Willebrand factor to detect high-risk atherosclerotic phenotype. JACC Cardiovasc Imaging. 2010;3:947–55.CrossRefPubMedPubMedCentral
25.
go back to reference Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, Lindner JR. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation. 2007;116:276–84.CrossRefPubMed Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, Lindner JR. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation. 2007;116:276–84.CrossRefPubMed
26.
go back to reference Lindner JR, Song J, Christiansen J, Klibanov AL, Xu F, Ley K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation. 2001;104:2107–12.CrossRefPubMed Lindner JR, Song J, Christiansen J, Klibanov AL, Xu F, Ley K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation. 2001;104:2107–12.CrossRefPubMed
27.
go back to reference Toma I, McCaffrey TA. Transforming growth factor-beta and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Cell Tissue Res. 2012;347:155–75.CrossRefPubMed Toma I, McCaffrey TA. Transforming growth factor-beta and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Cell Tissue Res. 2012;347:155–75.CrossRefPubMed
28.
go back to reference Chen PY, Qin L, Li G, Wang Z, Dahlman JE, Malagon-Lopez J, Gujja S, Cilfone NA, Kauffman KJ, Sun L, et al. Endothelial TGF-beta signalling drives vascular inflammation and atherosclerosis. Nat Metab. 2019;1:912–26.CrossRefPubMedPubMedCentral Chen PY, Qin L, Li G, Wang Z, Dahlman JE, Malagon-Lopez J, Gujja S, Cilfone NA, Kauffman KJ, Sun L, et al. Endothelial TGF-beta signalling drives vascular inflammation and atherosclerosis. Nat Metab. 2019;1:912–26.CrossRefPubMedPubMedCentral
29.
go back to reference Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol. 2003;41:1021–7.CrossRefPubMed Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol. 2003;41:1021–7.CrossRefPubMed
30.
go back to reference Ueland T, Otterdal K, Lekva T, Halvorsen B, Gabrielsen A, Sandberg WJ, Paulsson-Berne G, Pedersen TM, Folkersen L, Gullestad L, et al. Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1228–34.CrossRefPubMed Ueland T, Otterdal K, Lekva T, Halvorsen B, Gabrielsen A, Sandberg WJ, Paulsson-Berne G, Pedersen TM, Folkersen L, Gullestad L, et al. Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1228–34.CrossRefPubMed
31.
go back to reference Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887–96.CrossRefPubMedPubMedCentral Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887–96.CrossRefPubMedPubMedCentral
32.
go back to reference Theilmeier G, Michiels C, Spaepen E, Vreys I, Collen D, Vermylen J, Hoylaerts MF. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood. 2002;99:4486–93.CrossRefPubMed Theilmeier G, Michiels C, Spaepen E, Vreys I, Collen D, Vermylen J, Hoylaerts MF. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood. 2002;99:4486–93.CrossRefPubMed
33.
go back to reference Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in Von Willebrand factor-deficient mice. Blood. 2001;98:1424–8.CrossRefPubMed Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in Von Willebrand factor-deficient mice. Blood. 2001;98:1424–8.CrossRefPubMed
34.
go back to reference Gandhi C, Ahmad A, Wilson KM, Chauhan AK. ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism. J Thromb Haemost. 2014;12:255–60.CrossRefPubMed Gandhi C, Ahmad A, Wilson KM, Chauhan AK. ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism. J Thromb Haemost. 2014;12:255–60.CrossRefPubMed
35.
go back to reference Chung DW, Platten K, Ozawa K, Adili R, Pamir N, Nussdorfer F, St John A, Ling M, Le J, Harris J, et al. Low-density lipoprotein promotes microvascular thrombosis by enhancing Von Willebrand factor self-association. Blood. 2023;142:1156–66.CrossRefPubMed Chung DW, Platten K, Ozawa K, Adili R, Pamir N, Nussdorfer F, St John A, Ling M, Le J, Harris J, et al. Low-density lipoprotein promotes microvascular thrombosis by enhancing Von Willebrand factor self-association. Blood. 2023;142:1156–66.CrossRefPubMed
36.
go back to reference Brown E, Ozawa K, Moccetti F, Vinson A, Hodovan J, Nguyen TA, Bader L, Lopez JA, Kievit P, Shaw GD, et al. Arterial platelet adhesion in atherosclerosis-prone arteries of obese, insulin-resistant nonhuman Primates. J Am Heart Assoc. 2021;10:e019413.CrossRefPubMedPubMedCentral Brown E, Ozawa K, Moccetti F, Vinson A, Hodovan J, Nguyen TA, Bader L, Lopez JA, Kievit P, Shaw GD, et al. Arterial platelet adhesion in atherosclerosis-prone arteries of obese, insulin-resistant nonhuman Primates. J Am Heart Assoc. 2021;10:e019413.CrossRefPubMedPubMedCentral
37.
go back to reference Wang Y, Chen J, Ling M, Lopez JA, Chung DW, Fu X. Hypochlorous acid generated by neutrophils inactivates ADAMTS13: an oxidative mechanism for regulating ADAMTS13 proteolytic activity during inflammation. J Biol Chem. 2015;290:1422–31.CrossRefPubMed Wang Y, Chen J, Ling M, Lopez JA, Chung DW, Fu X. Hypochlorous acid generated by neutrophils inactivates ADAMTS13: an oxidative mechanism for regulating ADAMTS13 proteolytic activity during inflammation. J Biol Chem. 2015;290:1422–31.CrossRefPubMed
38.
go back to reference Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with Acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327:1771–81.CrossRefPubMedPubMedCentral Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with Acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327:1771–81.CrossRefPubMedPubMedCentral
Metadata
Title
Removal of endothelial surface-associated von villebrand factor suppresses accelerate datherosclerosis after myocardial infarction
Authors
Koya Ozawa
William Packwood
Matthew A Muller
Yue Qi
Aris Xie
Oleg Varlamov
Owen J. McCarty
Dominic Chung
José A. López
Jonathan R. Lindner
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2024
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-024-05231-6

Other articles of this Issue 1/2024

Journal of Translational Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.